ESMO Breast 2024 | De-escalation and escalation strategies for HER2+ breast cancer
Evandro de Azambuja
• 23 May 2024
Evandro De Azambuja, MD, PhD, Jules Bordet Institute, Brussels, Belgium, discusses de-escalation and escalation strategies in HER2-positive breast cancer, highlighting trials like COMPASS (NCT04266249), DECRESCENDO (NCT04675827), and KATHERINE (NCT01772472). These strategies involve the use of trastuzumab, pertuzumab, and trastuzumab emtansine (T-DM1) to optimize therapy based on patient response, aiming to reduce chemotherapy exposure while improving outcomes. This interview took place at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
